Tirzepatide: the ingredient in Zepbound and Mounjaro

Tirzepatide dosage, side effects and semaglutide vs tirzepatide, explained

Tirzepatide is the active ingredient in two FDA-approved weekly injections from Eli Lilly: Zepbound, approved for weight management and for obstructive sleep apnea with obesity, and Mounjaro, approved for type 2 diabetes and not for weight loss.1,2 Compounded tirzepatide also exists, and it is not FDA-approved. This page covers tirzepatide dosage, tirzepatide side effects, cost, and semaglutide vs tirzepatide.

  • Zepbound, Mounjaro and compounded tirzepatide, explained side by side
  • Intake reviewed by a U.S.-licensed provider, typically within 1 to 2 business days
  • Prior authorization help for brand-name tirzepatide on commercial insurance

FitRx membership costs $39 in month one and $135 a month from then on. Medication is a separate charge. Pictured: compounded tirzepatide. It is not FDA-approved, the FDA does not review it for safety, effectiveness or quality, and it is not a generic of Zepbound or Mounjaro. A provider decides what is appropriate, and not everyone qualifies.

Vial of compounded tirzepatide in front of a FitRx shipping box

What the main weight trial found

Adults on brand-name tirzepatide lost an average of 15.0% to 20.9% of their body weight in 72 weeks

SURMOUNT-1 followed adults with obesity, or with overweight, who did not have diabetes. They were randomly assigned to weekly tirzepatide or placebo for 72 weeks, alongside a reduced-calorie diet and more physical activity.3 The medicine was Eli Lilly’s tirzepatide, now sold as Zepbound.

Average weight loss was 15.0% on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg, against 3.1% on placebo. Starting weight averaged about 231 pounds. Adults with type 2 diabetes lost less in a second trial: 12.8% on 10 mg and 14.7% on 15 mg.1

These are group averages for brand-name tirzepatide. Compounded tirzepatide was not tested in these trials and is not FDA-approved, so the results cannot be assumed to apply to it.

Estimate it for your starting weight

230 lb
Weekly dose

Average weight lost in the trial

about 48 lb

Average change in body weight at 72 weeks in SURMOUNT-1, a trial of brand-name tirzepatide (Zepbound) with diet and exercise.1 Compounded tirzepatide was not tested. These are trial averages, not a forecast for you. Individual results vary.

Three forms of tirzepatide: Zepbound, Mounjaro and compounded

Tirzepatide acts on two receptors, GIP and GLP-1, and slows how quickly the stomach empties. It was first approved in the United States in 2022.1 It comes in three forms. Two are brand-name products with the same molecule and FDA approval. The third is a different category.

FDA-approved for weight management

Zepbound

Approved, with a reduced-calorie diet and more physical activity, to reduce excess body weight and keep it off in adults with obesity, or with overweight plus at least one weight-related condition. Also approved for moderate to severe obstructive sleep apnea in adults with obesity.1

FDA-approved for type 2 diabetes

Mounjaro

Approved to improve blood sugar in adults and children 10 and older with type 2 diabetes, and to lower the risk of major cardiovascular events in adults with type 2 diabetes at high risk.2

  • Same molecule and dose steps as Zepbound
  • Not FDA-approved for weight loss. See the Mounjaro page

Not FDA-approved

Compounded tirzepatide

Prepared by a state-licensed compounding pharmacy to fill a prescription. Through FitRx it starts at $216 a month with a 3-month supply, on top of membership, with shipping included.

  • Not a generic of Zepbound or Mounjaro, and not tested in their trials
  • Prescribed only if a licensed provider decides it is appropriate for you

Why the tag on the third card matters. Compounded drugs reach patients without FDA review of their safety, effectiveness or quality. In the agency’s words: “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”4 The section on compounded tirzepatide explains what that means in practice.

How getting tirzepatide through FitRx works

  1. Start with the intake

    You complete an online intake. It gives your provider what they need to judge whether tirzepatide is safe for you.

  2. A provider reads it

    A U.S.-licensed physician or nurse practitioner reviews it, typically within 1 to 2 business days, and decides whether medication is appropriate. Sometimes it is not.

  3. Prescription and pharmacy

    If your provider prescribes, the prescription goes to a partner pharmacy. For Zepbound or Mounjaro on a commercial plan, FitRx submits the prior authorization. Most decisions arrive in 2 to 14 business days. Our GLP-1 insurance checker explains the process.

  4. Follow-up as doses change

    The labeled starting dose is 2.5 mg a week. After that, you can message your provider whenever you need to and meet by video or phone each month.

Zepbound’s label covers adults with a BMI of 30 or higher, and adults with a BMI of 27 or higher who have at least one weight-related condition.1 The BMI calculator shows where you stand. FitRx treats adults 18 and older, and the provider makes the final call.

Start your intake

What a FitRx membership covers, whichever form you use

Your provider

Review of your intake, secure messaging with no cap on how often you write, and a video or phone visit every month.

Coach and coordinator

A dedicated coach, plus a care coordinator you can message.

Insurance paperwork

A team that submits prior authorizations for brand-name GLP-1 medications and, after a denial, can resubmit, up to three requests.

The price: $39 for the first month and $135 a month after that, billed monthly. Cancel any time in the patient portal. A membership cannot be paused, and it must stay active to keep a prior authorization. Longer plans are discounted, and HSA and FSA cards are accepted.

Not in the price: the medication. Zepbound or Mounjaro is paid for at the pharmacy, at a copay or cash price FitRx does not set. Compounded tirzepatide, which is not FDA-approved, is billed separately. FitRx does not work with government insurance (Medicare, Medicaid or TRICARE).

Tirzepatide side effects: the common ones and the serious ones

Most tirzepatide side effects involve the stomach and gut.1,2 The figures below come from the brand-name trials. Compounded tirzepatide is not FDA-approved and was not part of these studies, so no comparable figures exist for it.

Side effectPlacebo, Zepbound trialsTirzepatide, Zepbound trialsPlacebo, Mounjaro trialsTirzepatide, Mounjaro trials
Nausea8%25% to 29%4%12% to 18%
Diarrhea8%19% to 23%9%12% to 17%
Vomiting2%8% to 13%2%5% to 9%
Constipation5%11% to 17%1%6% to 7%
Stomach (abdominal) pain5%9% to 10%4%5% to 6%
Indigestion4%9% to 10%3%5% to 8%

Share of people reporting each reaction across the 5 mg, 10 mg and 15 mg doses, in pooled weight management trials (Zepbound) and pooled type 2 diabetes trials (Mounjaro).1,2 The trials enrolled different people, so compare the columns loosely.

In the Mounjaro trials, 3.0% to 6.6% of people on tirzepatide stopped treatment because of a gastrointestinal reaction, depending on dose.2 The Zepbound trials also recorded injection site reactions (6% to 8% on tirzepatide, 2% on placebo), fatigue (5% to 7%, against 3%) and hair loss (4% to 5%, against 1%).1

When they show up, and what helps

Dose increases are the usual trigger. In SURMOUNT-5, most adverse events were gastrointestinal, mild to moderate, and concentrated in the period when doses were going up.5 The label starts at 2.5 mg and requires at least four weeks on each dose before the next step.1 Four weeks is a minimum, so tell your provider if a new dose is hard on you.

The medication guides say to drink fluids when you have nausea, vomiting or diarrhea, because dehydration is behind the kidney injury named on the label.1

Serious risks and their warning signs

  • Thyroid C-cell tumors. Both labels carry a boxed warning because tirzepatide caused these tumors in rats. The risk in people is not known. Report a lump or swelling in the neck, hoarseness, trouble swallowing or shortness of breath.
  • Pancreatitis. Severe pain in the stomach area that will not go away, with or without vomiting, sometimes felt in the back.
  • Gallbladder problems. Upper stomach pain, fever, yellowing of the skin or eyes, or clay-colored stools.
  • Also on the labels: serious allergic reactions, low blood sugar when combined with insulin or a sulfonylurea, diabetic retinopathy complications in people with type 2 diabetes, severe stomach reactions (tirzepatide is not recommended in severe gastroparesis), and aspiration during general anesthesia or deep sedation.

The important safety information has the full list, including the effect on birth control pills. For the whole drug class, read our guide to GLP-1 side effects.

Tirzepatide dosage: how the weekly dose builds from 2.5 mg to 15 mg

Brand-name tirzepatide is injected under the skin once a week, at any time of day, with or without a meal. The tirzepatide dosage begins low and rises in 2.5 mg steps, with at least four weeks at each dose.1

Weekly doseEarliest point the label allowsWhat the dose is for
2.5 mgWeeks 1 to 4Starting dose, not a maintenance dose
5 mgWeek 5Lowest maintenance dose for weight management
7.5 mgWeek 9Step between 5 mg and 10 mg
10 mgWeek 13Maintenance dose
12.5 mgWeek 17Step between 10 mg and 15 mg
15 mgWeek 21Maintenance dose, and the maximum

Dose steps from the Zepbound and Mounjaro prescribing information.1,2 The weeks are our arithmetic from the four-week minimum: the quickest schedule the label permits. A provider can hold a dose for longer.

Maintenance doses

  • Weight management (Zepbound): 5 mg, 10 mg or 15 mg a week.
  • Obstructive sleep apnea with obesity (Zepbound): 10 mg or 15 mg a week.
  • Type 2 diabetes (Mounjaro, not approved for weight loss): raised from 2.5 mg only when more blood sugar control is needed, to a maximum of 15 mg in adults and 10 mg in pediatric patients.
  • Compounded tirzepatide: it is not FDA-approved and has no label of its own. The dose is whatever your provider writes on the prescription.

If you miss a dose

Under both labels, take the missed dose as soon as you can within 4 days (96 hours). Past 4 days, skip it and take the next dose on your normal day. You may change your injection day as long as two doses are at least 3 days (72 hours) apart.1,2

Pens, KwikPens and vials

  • Single-dose pen. One fixed dose per pen, in six strengths.
  • Single-dose vial. Lilly’s vial holds one dose in 0.5 mL, drawn up with a syringe.
  • KwikPen or multi-dose vial. Four weekly doses of 0.6 mL each. A KwikPen is never shared, and the label does not recommend it for self-injection by people who are visually impaired.
  • Compounded vial. Also drawn up with a syringe, but Lilly’s volumes do not apply to it. Use your prescription and pharmacy label.

Inject into the abdomen or thigh, or the back of the upper arm if someone else gives the injection, and rotate sites.1

A syringe marked in units measures volume, not milligrams, so the units that equal a milligram dose depend on the concentration printed on a vial’s label. If you measure a compounded vial this way, see our guide to tirzepatide dosing for weight loss in units.

What happens after stopping

In SURMOUNT-4, adults took tirzepatide for 36 weeks and lost an average of 20.9% of their weight. They were then assigned to continue or to switch to placebo. By week 88, those who continued had lost a further 5.5%, and those who stopped had regained 14.0%.6 Talk with your provider before stopping.

Semaglutide vs tirzepatide: the head-to-head result and the differences

One trial has tested the two against each other for weight loss. SURMOUNT-5 enrolled 751 adults with obesity who did not have diabetes. Each took tirzepatide or semaglutide for 72 weeks, at the highest dose they could tolerate. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. Waist size fell by an average of 18.4 cm and 13.0 cm. Most adverse events were gastrointestinal and mild to moderate.5

Point of comparisonTirzepatideSemaglutide
Brand names and makerZepbound, Mounjaro (Eli Lilly)Wegovy, Ozempic (Novo Nordisk)
How it actsGIP and GLP-1 receptor agonistGLP-1 receptor agonist
Approved for weight managementZepboundWegovy
Approved for type 2 diabetes, not weight lossMounjaroOzempic
Other approved usesZepbound: obstructive sleep apnea with obesity. Mounjaro: cardiovascular risk reduction in adults with type 2 diabetes at high risk.Wegovy: cardiovascular risk reduction in adults with established cardiovascular disease and obesity or overweight; MASH. Ozempic: cardiovascular and kidney risk reduction in certain adults with type 2 diabetes.
Weight loss, head to head (72 weeks)20.2%13.7%
Weight loss in separate placebo trials15.0% to 20.9%, placebo 3.1% (72 weeks)14.9%, placebo 2.4% (68 weeks)
Weekly dose range2.5 mg to 15 mgWegovy: 0.25 mg to 2.4 mg, with a 7.2 mg option
Nausea in weight management trials25% to 29%, placebo 8%44%, placebo 16%
Compounded, through FitRx (not FDA-approved)From $216 a month with a 3-month supplyFrom $151 a month with a 3-month supply

Sources: SURMOUNT-5 and each product’s prescribing information.1,2,5,7,8 Rates from separate trials are not a direct comparison. Compounded semaglutide and compounded tirzepatide are not FDA-approved, are not generics of the brands, and were not tested in these trials. FitRx prices are for medication only.

What a provider weighs besides the averages

A bigger average is one input. Your provider also looks at which approved uses match your health, what your plan covers, and how you tolerate each medicine. Form can matter too: tirzepatide is injection only, while Wegovy also comes as a once-daily tablet.7

The two are not used together: Zepbound’s label says it is not recommended alongside any GLP-1 receptor agonist, and semaglutide is one.1 For the diabetes brands, see our Mounjaro vs. Ozempic guide. For the other ingredient, see the semaglutide page.

Tirzepatide cost: list prices, savings cards, LillyDirect and compounded prices

Eli Lilly lists Zepbound at $499 to $1,086.37 per fill and Mounjaro at $1,112.16 per fill.9,10 What you actually pay depends on the form, your insurance and the reason for the prescription. These are the published terms as of November 18, 2026.

RouteWhat you could payConditions
Zepbound, commercial insurance covers itAs little as $25 for a 1-, 2- or 3-month fill of single-dose pensSavings card. Saves up to $100 per 1-month fill, $200 per 2-month, $300 per 3-month, and $1,300 a calendar year.
Zepbound, commercial insurance does not cover itAs low as $499 for a 1-month fill of single-dose pensSavings card.
Zepbound, self-pay through LillyDirect$299 a month (2.5 mg), $399 (5 mg), $449 (7.5 mg to 15 mg)KwikPen or single-dose vials. $449 requires a refill within 45 days.
Mounjaro, commercial insurance covers itAs little as $25 for a 1-, 2- or 3-month fill of single-dose pensSavings card, type 2 diabetes only. Saves up to $150 per 1-month fill, $300 per 2-month, $450 per 3-month, and $1,950 a calendar year.
Mounjaro, commercial insurance does not cover itAs low as $499 for a 1-month fillSavings card. Saves up to $647 a month and $8,411 a year.
Mounjaro, self-pay through LillyDirectStarting at $499 a month at every doseSingle-dose prefilled pen.
Compounded tirzepatide through FitRxFrom $216 a month with a 3-month supplyNot FDA-approved. Medication only. Shipping included.

Sources: Lilly’s savings and LillyDirect pages for Zepbound and Mounjaro.11,12,13,14 Prices and terms change. Confirm them with Lilly or your pharmacy before you fill.

The two savings cards

There is no coupon for tirzepatide as an ingredient. Each brand has its own copay card for people with commercial insurance, good for up to 13 fills a year. A month means 28 days and up to four pens, and both cards expire on December 31, 2026. People on government-funded programs such as Medicare, Medicaid and TRICARE are excluded. The Mounjaro card requires a prescription for an FDA-approved use, so one written only for weight loss does not qualify.11,13

LillyDirect self-pay prices

LillyDirect is Lilly’s pharmacy service. It fills and delivers prescriptions, but a prescriber still has to send one. The $449 Zepbound price belongs to Lilly’s Zepbound Journey Program, which requires each refill within 45 days. Refill later and 7.5 mg costs $499, while 10 mg, 12.5 mg and 15 mg cost $699. A month is 28 days: one KwikPen or four vials. Pen needles, or needles and syringes for vials, are bought separately, and single-dose vials are self-pay only.12

FitRx compounded prices

As of November 18, 2026, compounded tirzepatide through FitRx starts at $216 a month with a 3-month supply. That covers the medication and shipping, on top of membership ($39 for the first month, then $135 a month). A 1-month supply is also available; check its price when you sign up. A bundled plan puts provider care and compounded tirzepatide in one price: $349 for the first month, then $449 a month. Compounded tirzepatide is not FDA-approved and is not a generic of Zepbound or Mounjaro.

Compounded tirzepatide is not a generic: what it is and what the FDA says

A generic is a copy of a brand-name drug that the FDA has reviewed and approved. Compounded tirzepatide is not that, and it is not FDA-approved. A compounding pharmacy prepares it to fill a prescription, and the FDA does not review it for safety, effectiveness or quality.4,15 It is not Zepbound or Mounjaro, and it was not the product in any trial quoted on this page.

When the FDA says compounding may be appropriate

The agency’s position is narrow. A compounded drug might be appropriate when a patient’s medical need cannot be met by an FDA-approved drug, or when the approved drug is not commercially available. Its wording: “Compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug.”4

On availability, the FDA’s shortage database listed no current shortage of any tirzepatide injection on November 18, 2026.16 Our GLP-1 supply tracker shows the latest status. Whether a compounded medication is appropriate for you is a judgment for a licensed provider who has reviewed your history.

The FDA’s safety points

  • Dosing errors. The FDA has received reports of adverse events, some requiring hospitalization, that may be related to dosing errors with compounded injectable semaglutide: patients measuring the wrong dose and clinicians miscalculating doses. It has also received reports tied to doses beyond the approved label and to faster dose increases.4,17 That alert concerned semaglutide. Compounded tirzepatide is also measured from a vial with a syringe, so check your label each time.
  • Adverse event reports. By May 31, 2026, the FDA had received more than 730 for compounded tirzepatide. It notes that events are underreported and that the cause cannot always be determined.
  • Multi-dose vials. Discard a vial 28 days after first use, even if medicine remains, and use a new sterile needle and syringe for every dose.
  • Shipping. Do not use an injectable GLP-1 medication that arrives warm or without enough refrigeration.

Red flags the FDA lists for online sellers

  • A claim that a compounded drug is the same as an FDA-approved drug
  • Deep discounts that seem too good to be true
  • Medicine that looks different, or arrives damaged or without instructions
  • No screening and no prescription from a licensed doctor
  • No licensed doctor available afterwards
  • Spelling errors on the label, or a wrong pharmacy address

From the FDA’s page on unapproved GLP-1 drugs.4 The agency also says products sold “for research purposes” are illegal, and advises buying only from state-licensed pharmacies.

How FitRx handles compounded tirzepatide

  • A provider decides. A licensed provider reviews your intake before anything is prescribed, and may decide medication is not appropriate.
  • A licensed pharmacy prepares it. It comes from a state-licensed compounding pharmacy.
  • Supply and shipping. Supplies are for 1 month or 3 months; a 3-month supply ships as three vials in one box. Allow 2 to 7 business days for pharmacy processing, plus 2-day shipping.
  • Your dose comes from your prescription. We do not print vial strengths on this page. Follow your prescription and your pharmacy label, and message your provider if either is unclear. Membership includes unlimited secure messaging.
  • Bundle refund. If you choose a bundled plan and are not clinically eligible, FitRx refunds it under a 30-day guarantee on bundles.

Comparing tirzepatide with other medications: where to read more

The other medication pages follow the same layout as this one.

PageActive ingredientFDA-approved for
ZepboundTirzepatideWeight management; obstructive sleep apnea with obesity
MounjaroTirzepatideType 2 diabetes. Not approved for weight loss.
WegovySemaglutideWeight management; cardiovascular risk reduction; MASH
OzempicSemaglutideType 2 diabetes. Not approved for weight loss.
SemaglutideSemaglutideDepends on the brand. Compounded semaglutide is not FDA-approved.

Which one fits you is a question for a licensed provider.

A person messaging their FitRx care team in the patient portal on a phone

The FitRx care team

A licensed provider decides whether tirzepatide fits, and in which form

Zepbound, Mounjaro, compounded tirzepatide or no medication at all: that choice is a clinical one. A U.S.-licensed physician or nurse practitioner reads your intake and tells you what they recommend.

  • U.S.-licensed providers review every intake and make every prescribing decision
  • Unlimited secure messaging, plus monthly video or phone visits
  • A care coordinator and a coach alongside your provider
  • An insurance coordination team for brand-name GLP-1 prior authorizations

This page was written and reviewed by the FitRx care team and last updated November 18, 2026. It is general information, not personal medical advice.

Tirzepatide FAQs

What is tirzepatide?

Tirzepatide is a once-weekly injectable medicine from Eli Lilly that acts on two receptors, GIP and GLP-1. It is the active ingredient in two FDA-approved products: Zepbound, for weight management and for obstructive sleep apnea with obesity, and Mounjaro, for type 2 diabetes. Mounjaro is not approved for weight loss.

Is tirzepatide the same thing as Zepbound and Mounjaro?

Tirzepatide is the ingredient. Zepbound and Mounjaro are the brand names Eli Lilly sells it under, with the same dose steps and different approved uses. Compounded tirzepatide is a separate category: it is not FDA-approved and is not a generic of either brand.

What is the usual tirzepatide dosage?

Under the Zepbound label, treatment starts at 2.5 mg once a week for 4 weeks, then moves to 5 mg. The dose may then rise 2.5 mg at a time, with at least 4 weeks on each dose, to a maximum of 15 mg a week. Maintenance doses for weight management are 5 mg, 10 mg or 15 mg. Your provider decides which is right for you.

What should I do if I miss a dose of tirzepatide?

The Zepbound and Mounjaro labels say to take a missed dose as soon as possible within 4 days (96 hours). After 4 days, skip it and take the next dose on your regular day. You can change your injection day if two doses are at least 3 days (72 hours) apart.

What are the most common tirzepatide side effects?

Stomach and gut effects. In Zepbound's weight management trials, nausea was reported by 25% to 29% of adults on tirzepatide compared with 8% on placebo, and diarrhea by 19% to 23% compared with 8%. Vomiting, constipation, stomach pain and indigestion were also common. Rates were lower in Mounjaro's diabetes trials.

How long do tirzepatide side effects last?

It varies. In the SURMOUNT-5 trial, most adverse events were gastrointestinal, mild to moderate, and happened mainly while doses were being raised. The label requires at least 4 weeks on a dose before an increase. Tell your provider if side effects are severe or are not easing.

Semaglutide vs tirzepatide: which led to more weight loss?

In SURMOUNT-5, the trial that compared them directly, 751 adults with obesity and without diabetes took the highest dose they could tolerate for 72 weeks. Average weight loss was 20.2% with tirzepatide and 13.7% with semaglutide. Those are group averages. The right choice for a person also depends on health history, side effects and insurance.

How much weight do people lose on tirzepatide?

SURMOUNT-1 ran for 72 weeks in adults who did not have diabetes. The average loss was 15.0% of body weight on 5 mg, 19.5% on 10 mg and 20.9% on 15 mg. On placebo it was 3.1%. These results are for brand-name tirzepatide used with diet and exercise. Compounded tirzepatide was not tested in these trials, and individual results vary.

What happens when you stop taking tirzepatide?

In SURMOUNT-4, adults lost an average of 20.9% over 36 weeks on tirzepatide and were then assigned to continue or switch to placebo. By week 88, those who continued had lost a further 5.5%, and those on placebo had regained 14.0%. Talk with your provider before you stop.

How much does tirzepatide cost?

As of November 18, 2026, Zepbound or Mounjaro can cost as little as $25 a fill with commercial insurance that covers it and Lilly's savings card. Self-pay through LillyDirect, Zepbound is $299 a month for 2.5 mg, $399 for 5 mg and $449 for higher doses refilled within 45 days, and Mounjaro pens start at $499. Compounded tirzepatide through FitRx starts at $216 a month with a 3-month supply and is not FDA-approved. Membership is separate. Confirm prices before you fill.

Is there a tirzepatide coupon?

Not for the ingredient, but each brand has a savings card from Eli Lilly. With commercial insurance that covers the drug, either card can bring a fill to as little as $25. The Mounjaro card applies only to an FDA-approved use, which is type 2 diabetes. People on government programs such as Medicare or Medicaid are not eligible. Both cards expire December 31, 2026.

Is compounded tirzepatide a generic of Zepbound or Mounjaro?

No. A generic is a copy of a brand-name drug that the FDA has reviewed and approved. Compounded tirzepatide is prepared by a compounding pharmacy and is not FDA-approved: the FDA does not review it for safety, effectiveness or quality, and it was not tested in the brand-name trials. A licensed provider decides whether it is appropriate for you.

How do I measure compounded tirzepatide in units?

Start with your prescription and the label on your vial. Units on a syringe measure volume, so the units that match your milligram dose depend on the concentration printed on your own vial. The FDA has received reports of patients measuring the wrong dose of compounded injectable semaglutide, so ask your provider or pharmacy if anything is unclear. Compounded tirzepatide is not FDA-approved.

Is tirzepatide approved for sleep apnea?

One tirzepatide product is. Zepbound is FDA-approved for moderate to severe obstructive sleep apnea in adults with obesity. In the two trials behind the approval, breathing interruptions fell by about 25 to 29 events an hour on Zepbound at week 52, compared with about 5 on placebo. Mounjaro and compounded tirzepatide are not approved for sleep apnea.

Is tirzepatide included in the FitRx membership price?

No. Membership is $39 for the first month and $135 a month after that. It covers provider care, messaging, monthly visits, coaching and insurance coordination for brand-name GLP-1 medications. Medication is billed separately. FitRx does not work with government insurance, and a provider may decide medication is not appropriate.

Important safety information for tirzepatide (Zepbound and Mounjaro)

Boxed warning: risk of thyroid C-cell tumors. Zepbound and Mounjaro both carry this warning. Tirzepatide caused thyroid C-cell tumors in rats. It is not known whether tirzepatide causes these tumors, including medullary thyroid carcinoma (MTC), in people. Do not use tirzepatide if you or a family member has ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Tell your provider about a lump or swelling in your neck, hoarseness, trouble swallowing or shortness of breath.

What the approved products are for. Zepbound (tirzepatide) is used with a reduced-calorie diet and increased physical activity for weight reduction and maintenance in adults with obesity, or with overweight and at least one weight-related condition, and to treat moderate to severe obstructive sleep apnea in adults with obesity.1 Mounjaro (tirzepatide) is used with diet and exercise to improve blood sugar in adults and children 10 and older with type 2 diabetes, and to reduce major cardiovascular events in adults with type 2 diabetes at high risk. It is not approved for weight loss.2 Zepbound is not recommended with other tirzepatide products or any GLP-1 receptor agonist.

Who should not use tirzepatide. Anyone with a personal or family history of MTC, anyone with MEN 2, and anyone who has had a serious allergic reaction to tirzepatide.

Warnings and precautions. The Zepbound and Mounjaro labels warn about:

  • Acute pancreatitis. Stop the medicine and get medical help for severe stomach pain that does not go away.
  • Severe gastrointestinal reactions. Tirzepatide is not recommended in severe gastroparesis.
  • Acute kidney injury from fluid loss caused by vomiting or diarrhea.
  • Acute gallbladder disease.
  • Serious allergic reactions, including anaphylaxis and angioedema.
  • Low blood sugar when used with insulin or a medicine such as a sulfonylurea.
  • Diabetic retinopathy complications in people with type 2 diabetes.
  • Food or liquid entering the lungs during general anesthesia or deep sedation. Tell your providers about planned surgeries or procedures.

A KwikPen is for one person and must never be shared.

Most common side effects (5% or more of people). Zepbound: nausea, diarrhea, vomiting, constipation, abdominal pain, indigestion, injection site reactions, fatigue, allergic reactions, belching, hair loss and gastroesophageal reflux. Mounjaro: nausea, diarrhea, decreased appetite, vomiting, constipation, indigestion and abdominal pain.

Pregnancy and birth control. Tirzepatide may harm an unborn baby. Stop Zepbound when pregnancy is recognized. Birth control pills may be less effective: switch to a non-oral method, or add a barrier method, for 4 weeks after starting and for 4 weeks after each dose increase.

Other medicines and fluids. Tirzepatide delays stomach emptying and may change how medicines taken by mouth are absorbed. Drink fluids to lower the chance of dehydration if you have nausea, vomiting or diarrhea.

This summary does not replace the full prescribing information for Zepbound or Mounjaro, or a conversation with your provider.1,2 Side effects can be reported to the FDA at www.fda.gov/medwatch or 1-800-FDA-1088.

About compounded tirzepatide. Compounded tirzepatide is not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality. It is not a generic of Zepbound or Mounjaro and was not studied in their clinical trials. A licensed provider decides whether a compounded medication is appropriate for you.4

Ask a licensed provider whether tirzepatide is right for you

Complete the online intake. A licensed provider reviews it and tells you whether they recommend tirzepatide, which form, or something else.

Get started

FitRx membership costs $39 in month one and $135 a month from then on. Medication is a separate charge. Not everyone qualifies.

References (17)
  1. Zepbound (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/zepbound-uspi.pdf
  2. Mounjaro (tirzepatide) injection. Prescribing information. Eli Lilly and Company; revised August 2026. https://pi.lilly.com/us/mounjaro-uspi.pdf
  3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
  4. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
  5. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393(1):26-36. https://pubmed.ncbi.nlm.nih.gov/40353578/
  6. Aronne LJ, Sattar N, Horn DB, et al. Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. https://pubmed.ncbi.nlm.nih.gov/38078870/
  7. Wegovy (semaglutide) injection and tablets. Prescribing information. Novo Nordisk; revised June 2026. https://www.novo-pi.com/wegovy.pdf
  8. Ozempic (semaglutide) injection. Prescribing information. Novo Nordisk; revised May 2026. https://www.novo-pi.com/ozempic.pdf
  9. Eli Lilly and Company. Zepbound pricing information (list price). https://pricinginfo.lilly.com/zepbound
  10. Eli Lilly and Company. Mounjaro pricing information (list price). https://pricinginfo.lilly.com/mounjaro
  11. Eli Lilly and Company. Zepbound savings and support, including Savings Card terms and conditions. https://zepbound.lilly.com/savings
  12. Eli Lilly and Company. LillyDirect: Zepbound self-pay pricing and pharmacy options. https://www.lilly.com/lillydirect/medicines/zepbound
  13. Eli Lilly and Company. Mounjaro savings and coverage, including Savings Card terms and conditions. https://mounjaro.lilly.com/savings-coverage
  14. Eli Lilly and Company. LillyDirect: Mounjaro self-pay pricing and pharmacy options. https://www.lilly.com/lillydirect/medicines/mounjaro
  15. U.S. Food and Drug Administration. Compounding and the FDA: questions and answers. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
  16. U.S. Food and Drug Administration. FDA Drug Shortages database. https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
  17. U.S. Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. https://www.fda.gov/drugs/human-drug-compounding/fda-alerts-health-care-providers-compounders-and-patients-dosing-errors-associated-compounded

Sources were opened and checked on November 18, 2026. Prices, savings programs and labels change; confirm current terms with the manufacturer, your pharmacy or your provider.